Quadrant Capital Group LLC Sells 362 Shares of Edwards Lifesciences Corp (NYSE:EW)

Quadrant Capital Group LLC cut its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 22.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,284 shares of the medical research company’s stock after selling 362 shares during the quarter. Quadrant Capital Group LLC’s holdings in Edwards Lifesciences were worth $225,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BB&T Corp increased its holdings in Edwards Lifesciences by 16.5% in the 2nd quarter. BB&T Corp now owns 3,383 shares of the medical research company’s stock worth $625,000 after buying an additional 480 shares in the last quarter. Moody Lynn & Lieberson LLC increased its holdings in Edwards Lifesciences by 680.4% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 28,875 shares of the medical research company’s stock worth $5,334,000 after buying an additional 25,175 shares in the last quarter. Nippon Life Global Investors Americas Inc. increased its holdings in Edwards Lifesciences by 44.2% in the 2nd quarter. Nippon Life Global Investors Americas Inc. now owns 15,690 shares of the medical research company’s stock worth $2,899,000 after buying an additional 4,810 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in Edwards Lifesciences by 16.6% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 69,438 shares of the medical research company’s stock worth $12,828,000 after buying an additional 9,902 shares in the last quarter. Finally, World Asset Management Inc increased its holdings in Edwards Lifesciences by 1.9% in the 2nd quarter. World Asset Management Inc now owns 14,290 shares of the medical research company’s stock worth $2,640,000 after buying an additional 262 shares in the last quarter. Hedge funds and other institutional investors own 82.42% of the company’s stock.

EW traded up $1.50 on Tuesday, hitting $210.93. 9,611 shares of the company’s stock traded hands, compared to its average volume of 1,250,306. The firm has a 50 day simple moving average of $196.10. The company has a market capitalization of $44.58 billion, a price-to-earnings ratio of 44.64, a price-to-earnings-growth ratio of 2.70 and a beta of 0.87. Edwards Lifesciences Corp has a one year low of $134.53 and a one year high of $219.71. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the company earned $1.24 EPS. Equities analysts predict that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $178.99, for a total value of $5,870,872.00. Following the sale, the chief executive officer now owns 84,601 shares of the company’s stock, valued at approximately $15,142,732.99. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 300 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $178.54, for a total value of $53,562.00. Following the completion of the sale, the vice president now directly owns 19,415 shares in the company, valued at approximately $3,466,354.10. The disclosure for this sale can be found here. Insiders have sold a total of 172,153 shares of company stock worth $32,961,920 in the last three months. 1.63% of the stock is owned by corporate insiders.

EW has been the subject of several research analyst reports. BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a report on Thursday, July 25th. Bank of America reissued a “buy” rating and issued a $225.00 target price (up from $215.00) on shares of Edwards Lifesciences in a research report on Wednesday, July 24th. Wells Fargo & Co raised their target price on Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Raymond James raised their target price on Edwards Lifesciences from $200.00 to $232.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group raised their target price on Edwards Lifesciences from $210.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $204.74.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: What is a stock portfolio tracker?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.